Holen Sie sich die Stockscreener-App
315.80
2.92%
-9.50
Handel nachbörslich:
315.80
Schlusskurs vom Vortag:
$325.30
Offen:
$325.3
24-Stunden-Volumen:
296.03K
Relative Volume:
0.63
Marktkapitalisierung:
$8.80B
Einnahmen:
$7.46M
Nettoeinkommen (Verlust:
$-326.53M
KGV:
-23.60
EPS:
-13.3803
Netto-Cashflow:
$-282.53M
1W Leistung:
+3.73%
1M Leistung:
-3.66%
6M Leistung:
+0.33%
1J Leistung:
+433.27%
1-Tages-Spanne:
$315.70
$330.00
1-Wochen-Bereich:
$304.00
$330.00
52-Wochen-Spanne:
$37.19
$366.52
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
315.80 | 9.07B | 7.46M | -326.53M | -282.53M | -13.38 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-13 | Eingeleitet | Goldman | Buy |
| 2026-06-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-04-10 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-02 | Eingeleitet | Wells Fargo | Equal Weight |
| 2025-12-15 | Bestätigt | Oppenheimer | Outperform |
| 2025-11-19 | Eingeleitet | BTIG Research | Buy |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines Inc (PRAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Praxis Precision Medicines Inc (PRAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Orbimed Advisors LLC Raises Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
SummitTX Capital L.P. Sells 4,791 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
TradingKey - TradingKey
PRAX|Praxis Precision Medicines Inc|Price:325.300|Chg%:+2.900 - TradingKey
Swiss National Bank Acquires 6,200 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Fifth Third Bancorp Acquires New Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Allspring Global Investments Holdings LLC Grows Stake in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
California Public Employees Retirement System Takes $13.58 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Affinity Asset Advisors LLC Has $54.77 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. Revenue Breakdown – NASDAQ:PRAX - TradingView
Praxis Precision Medicines Inc (PRAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Understanding the Setup: (PRAX) and Scalable Risk - Stock Traders Daily
ETFs Investing in Praxis Precision Medicines, Inc. Stocks - TradingView
Praxis Precision Medicines: Priced For Half Of What I Think It's Worth (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (PRAX) Bank of America Global Healthcare Conference 2026 summary - Quartr
PRAX stock trades around recent lows as Praxis Precision Medicines updates pipeline and cash runway - AD HOC NEWS
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Praxis Precision Medicines (PRAX), Sino Biopharmaceutical (SBMFF) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Piper Sandler reiterates Praxis Precision Medicines stock rating By Investing.com - Investing.com Nigeria
PRAX Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
Piper Sandler reiterates Praxis Precision Medicines stock rating - Investing.com
Piper Sandler Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,200 - Moomoo
Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating - Investing.com
Praxis Precision Shares Rally On Price Target Hikes: Analyst Sees Upside As High As 100% For Stock - Stocktwits
Candriam S.C.A. Has $20.50 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
RBC Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $449 - Moomoo
Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says - Moomoo
Praxis Precision Medicines explores neurology pipeline as Nasdaq-listed biotech refines its focus - Ad Hoc News
Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com - Investing.com Nigeria
Praxis Precision Medicines Inc. (PRAX) Q1 2026 Earnings: Surprise Beat on EPS as Clinical Pipeline AdvancesRevenue Miss Report - dars.gov.et
Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495 - Stock Titan
Praxis Precision (PRAX) Partners with Remagine Labs for Innovati - GuruFocus
Praxis Precision Medicines Partners with Remagine Labs to Develop Innovative Transdermal Patch for Ulixacaltamide Delivery in Essential Tremor – Minichart - Minichart
Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor - Stock Titan
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor - Investing News Network
Praxis bets on skin patch for essential tremor drug - Stock Titan
Praxis Precision Medicines and Remagine Labs Announce - GlobeNewswire
S&P 500 Futures Climb In Premarket Trading; Praxis Precision Meds, IREN Lead - Moomoo
S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead - Barron's
If You Invested $1,000 in Praxis Precision Medicines, Inc. (PRAX) - Stock Titan
PRAX stock. Praxis Precision Medicines holds the spotlight on thin news - Ad-hoc-news.de
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor - Stock Titan
Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Enterprise value to revenue forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Jefferies Keeps Their Buy Rating on Praxis Precision Medicines (PRAX) - The Globe and Mail
Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX - TradingView
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):